Changes hospital payment rules for rare disease drugs

File HF4349 ("Changes hospital payment rules for rare disease drugs") is before the Minnesota Legislature and has not been decided. Latest step (March 16, 2026): Introduction and first reading, referred to.

Minnesota file HF4349, before the Minnesota Legislature. Still to be decided as of 2026-03-16.

What it does

Hospital access to rare disease biologics may shift Patients treated at hospitals for rare diseases using biological products may experience changes in drug availability or out-of-pocket costs depending on how hospitals adjust pricing and inventory decisions under the new reimbursement rules.

The bigger picture

Hospital margins and insurance costs likely affected Hospitals' profitability on rare-disease treatments and health insurance premiums across Minnesota could shift if the reimbursement changes alter how much hospitals recoup for expensive biologics.

Official summary

Provisions governing hospital reimbursement for biological products to treat rare diseases modified.

Read the official record for HF4349

See everything up for a vote · This week in Minnesota · See what we have filed with the clerk